Lantheus Holdings, Inc. entered into a collaboration and license agreement with privately-held NanoMab Technology to develop an imaging biomarker research tool.
- Lantheus to license NanoMab’s anti-PD-L1 imaging biomarker NM-01 as part of agreement
- NM-01 is in Phase 1 clinical development; NanoMab plans to file an Investigational Medicinal Product Dossier (IMPD) in the United Kingdom in the second half of 2019
Link to Statement: Lantheus Announces Strategic Collaboration with NanoMab to Provide a Novel Biomarker for Clinical Development and Management of Immuno-Oncology Therapies
©2019 Bloomberg L.P. All rights reserved. Used with permission
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.